Mobile Health Intervention to Improve Exercise in Pediatric PH

To assess the effect of a mHealth intervention or no intervention on average daily step count from baseline to 12 weeks.

Accelerometry is a direct measure of physical activity in patients' day-to-day lives. Step counts will be measured using the Fitbit device monitor, a lightweight device that has a three-axis acceleration sensor, altimeter, vibration motor, and optical heart rate monitor.

To assess the effect of a mHealth intervention or no intervention on quality of life between baseline and Week 12.

The SF36 is one of the most widely used generic measures of subjective health status. The SF36 includes one multi-item scale that assesses eight health concepts.

Scoring the SF 36-Item Health Survey is a two-step process. First, precoded numeric values are recoded per a scoring key. All items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the low

To assess the effect of a mHealth intervention or no intervention on quality of life between baseline and Week 12.

The emPHasis-10 is a pulmonary hypertension-specific questionnaire to assess health related quality of life. It covers breathlessness, fatigue and lack of energy, social restrictions, and concerns regarding effects on patient's significant others, such as family and friends. Each item is scored on a semantic differential six-point scale (0-5), with contrasting adjectives at each end. A total emPHasis-10 score is derived using simple aggregation of the 10 items. emPHasis-10 scores range from 0 to 50, higher scores indicate worse quality of life.

To assess the effect of a mHealth intervention or no intervention on quality of life between baseline and Week 12.

The Pediatric Quality of Life Inventory (PedsQL) Measurement Model is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL integrates seamlessly both generic core scales and disease-specific modules into one measurement system, which generally takes about 4 minutes to complete. Each item is scored on a 5-point Likert scale from 0 (Never) to 4 (Almost always), then reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better health-related quality of life.

To assess the effect of a mHealth intervention or no intervention on quality of life between baseline and Week 12.

The PIP is a questionnaire comprising 42 items, grouped into four domains or subscales: medical care, communication, emotional functioning, and role function. Its purpose is to measure the levels of stress suffered by parents caring for a child with a chronic disease. Responses are provided using a five-point Likert scale, ranging from 1 ("never/not at all") to 5 ("very often/extremely"). Higher scores indicate higher levels of stress.

To assess the effect of a mHealth intervention or no intervention on total daily activity time from baseline to 12 weeks. Activity time is defined as time spent above 3 metabolic equivalents.

Accelerometry is a direct measure of physical activity in patients' day-to-day lives. Activity time will be measured using the Fitbit device monitor, a lightweight device that has a three-axis acceleration sensor, altimeter, vibration motor, and optical heart rate monitor.

To assess the effect of a mHealth intervention or no intervention on unadjusted change in raw daily steps from baseline to 12 weeks.

Accelerometry is a direct measure of physical activity in patients' day-to-day lives. Step counts and will be measured using the Fitbit device monitor, a lightweight device that has a three-axis acceleration sensor, altimeter, vibration motor, and optical heart rate monitor.

To assess the effect of a mHealth intervention or no intervention on total daily aerobic time from baseline to 12 weeks. Aerobic time is defined as the total time spent walking continuously for > 10 minutes without breaking for > 1 minute.

Accelerometry is a direct measure of physical activity in patients' day-to-day lives. Aerobic time will be measured using the Fitbit device monitor, a lightweight device that has a three-axis acceleration sensor, altimeter, vibration motor, and optical heart rate monitor.

To assess the effect of a mHealth intervention or no intervention on frequency (% days) of goal attainment from baseline to 12 weeks.

Accelerometry is a direct measure of physical activity in patients' day-to-day lives. Frequency (% days) of goal attainment will be measured using the Fitbit device monitor, a lightweight device that has a three-axis acceleration sensor, altimeter, vibration motor, and optical heart rate monitor.

To assess the effect of a mHealth intervention or no intervention on mean daily steps during week 12 and week 18.

Accelerometry is a direct measure of physical activity in patients' day-to-day lives. Step counts will be measured using the Fitbit device monitor, a lightweight device that has a three-axis acceleration sensor, altimeter, vibration motor, and optical heart rate monitor.

To assess the effect of a mHealth intervention or no intervention on B-type natriuretic peptide levels (pg/mL) between baseline and 12 weeks.

To assess the effect of a mHealth intervention or no intervention on the 6-minute walk test distance (meters) between baseline and 12 weeks.

To assess the effect of a mHealth intervention or no intervention on Echocardiographic pericardial effusion from baseline to 12 weeks.

To assess the effect of a mHealth intervention or no intervention on Echocardiographic maximal tricuspid regurgitant velocity from baseline to 12 weeks.

To assess the effect of a mHealth intervention or no intervention on Echocardiographic measurement of RV fractional area change (FAC) from baseline to 12 weeks.

To assess the effect of a mHealth intervention or no intervention on a composite outcome of PAH-related hospitalization, medication regimen escalation, decrease in vital status, and all-cause mortality at 12 weeks after randomization. Clinical worsening events are defined as death (all causes), hospitalizations due to worsening pulmonary arterial hypertension (PAH), escalation in WHO functional class, and initiation of an inhaled or infused prostacyclin (PGI2) for the treatment of worsening PAH.